Engineered immune cells for relapsed rhabdomyosarcoma in youth
Treatments studied
Part of Cancer clinical trials.
This early-phase trial tests a new immune cell therapy (CAR T cells) for children and young adults whose rhabdomyosarcoma has returned or not responded to standard treatments. The goal is to see if these specially engineered cells can find and attack the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 39 years old.
- You must weigh at least 33 pounds (15 kilograms).
- You must have rhabdomyosarcoma that came back or didn't go away after at least two previous cancer treatments.
- You must be willing to get blood transfusions if needed.
- Your heart, lungs, liver, kidneys, and bone marrow must be working well enough.
- You must agree to use effective birth control if you could become pregnant or get someone pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.
This early-phase study tests a lab-made immune therapy (CAR T cells) made from your own cells to treat children’s solid tumors that have a specific marker called B7-H3. It is designed for kids whose cancer has come back or did not respond to standard treatment, aiming to shrink tumors and keep the therapy safe.
This trial tests a new kind of immunotherapy for children and teens with solid tumors that have not responded to standard treatments. The therapy uses specially engineered T cells (CAR T cells) that target a protein called GPC3 found on many tumor cells, and it includes extra signals (IL-15 and IL-21) to help the T cells work better.
This trial tests a new immunotherapy that targets a protein called CCR4 on certain T-cell lymphomas. The treatment uses your own immune cells, modified to find and attack cancer cells, and may help when other treatments have stopped working.
This trial tests a combination of targeted radiation and special immune cells (CAR T cells) for children and young adults whose bone or soft tissue sarcoma has come back or not responded to standard treatments. The CAR T cells are made from your own blood cells and are designed to attack a protein called B7-H3 found on the sarcoma cells.
This trial tests a new kind of cell therapy called CAR T-cells that are engineered to find and attack sarcoma cells carrying a marker called B7-H3. It is for children and young adults whose sarcoma has come back or not gone away after treatment.
Hear when a new Rhabdomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.